bullish
Hutchmed China Ltd (13.HK/HCM.US) 24H1 - Fruquintinib's US Sales Beat; Break-Even Is Within Reach
233 Views07 Aug 2024 08:55
HUTCHMED's fruquintinib US sales and savolitinib combination with osimertinib for NSCLC will drive future growth. Breakeven in 2025 is expected and overseas market sales could exceed US$300m in 2024.
What is covered in the Full Insight:
- Introduction
- Sales Performance Highlights
- Key Product Updates
- Financial Review and Cost Control
- Valuation and Future Outlook
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- CanSino Biologics (6185.HK/688185.CH) - Breakeven May Arrive Earlier than Expected23 Oct 2024
- 2024 High Conviction Update: Innovent (1801.HK) 24Q2 - Valuation Upside Will Be Further Opened Up13 Aug 2024
- China Healthcare Weekly (Aug.11) - 2024 NRDL Negotiation, China Biotech Outlook, Bottom Fish CanSino11 Aug 2024
- Hutchmed China Ltd (13.HK/HCM.US) - Time to Reassess Valuation Prospects Despite the Pain Points19 Jun 2024
- Hutchmed China Ltd (13.HK/HCM.US) - High Growth Is Expected from 2024 to 202612 Mar 2024
- Hutchmed China Ltd (13.HK/HCM.US) - 2023 Results Preview and Catalysts in 202420 Feb 2024
x